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HEPATITIS B IN POLAND
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Unimed Research Centre for Pharmacoeconomics, Warsaw, 
Poland
OBJECTIVES: To estimate the C/E of lamivudine in the
treatment of chronic hepatitis B (CHB) in Poland.
METHODS: Model for the Polish health-care context
was developed, based on the use of clinical data from lit-
erature and local data on health-care resource utilisation
and unit cost. Costs and effects of a population of CHB
patients were modelled using 4 scenarios, which attempt
to reflect real-life practice, in which patients may receive
any of the treatment options available and a proportion
of patients may still receive no treatment because therapy
is not suitable. Scenario A and B assumed the availability
of both treatment options: the first choice of treatment is
in A-lamivudine and in B-INFa. In scenario C the only
approved treatment is INFa, in scenario D patient re-
ceived no antiviral treatment. The measure of outcomes
were: HBeAg seroconversion and nonprogression to cir-
rhosis. Only direct medical costs were analysed. The per-
spective of health-care payers and time horizon of 1 year
were taken. The one-way sensitivity analysis and extreme
scenario analysis were performed. RESULTS: The best
results in terms of seroconversion and nonprogression to
cirrhosis were achieved in scenario A, costs were lowest
in scenario D. Mean cost/HBeAg seroconvertion and
mean cost/cirrhosis avoided were (in PLN, 1 USD  4
PLN): for A—35238 and 6480, for B—72654 and
16289, for C—49370 and 8689, for D—20985 and
1474. The incremental analysis vs scenario D indicated,
that A is a more cost-effective alternative than B and C.
Changing in value of key drivers for sensitivity analysis
did not have any significant effect on the ICER. CON-
CLUSIONS: Lamivudine as the first choice treatment of
CHB (scenario A) allows to receive the best results in
terms of seroconversion and nonprogression to cirrhosis.
This is the most cost-effective alternative to “no treat-
ment” (scenario D).
PID22
AN APPRAISAL OF HEALTH-RELATED QUALITY 
OF LIFE INSTRUMENTS FOR USE IN PATIENTS 
DIAGNOSED WITH HUMAN 
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Joshi AV, Nau DP, Kalsekar ID
West Virginia University, Morgantown, WV, USA
OBJECTIVES: The increasing effectiveness of medical
treatments for HIV (Human Immunodeficiency Virus)
has increased survival time of patients infected with the
virus. Because of the high incidence of side effects and the
burden of complex medication regimens, an increased
emphasis has been placed on the assessment of health-
related quality of life (HRQL) in HIV patients. The pur-
pose of this study is to review and compare instruments
used for measuring HRQL in HIV patients. METHODS:
Clinical trials involving HIV patients were identified
through the use of MEDLINE and AIDSLINE. The
HRQL instruments used in these trials included: 1) ge-
neric instruments such as the Medical Outcomes Study
(MOS) Short-Form (SF-36), Sickness Impact Profile, Not-
tingham Health Profile; 2) utility-based measures such as
the Quality of Well-Being Scale and the Q-TWIST (Qual-
ity adjusted Time Without Symptoms of disease and Tox-
icity); and 3) disease-specific instruments such as the
Multidimensional Quality of Life questionnaire for HIV
(MQoL-HIV), Functional Assessment of HIV Infection
(FAHI) scale, HIV/AIDS-Targeted Quality of Life Instru-
ment (HAT-QoL), HIV Overview of Problem/Evaluation
System (HOPES) instrument, HIV Patient Reported Sta-
tus and Experience (HIV-PARSE) scale, and the MOS-
HIV scale. Criteria for evaluating the instruments in-
cluded: comprehensiveness, respondent burden, internal
consistency of scales, test-retest reliability, clinical valid-
ity, and responsiveness to change. RESULTS: No instru-
ment was found to be completely devoid of ceiling ef-
fects. Although none of the instruments demonstrated
perfect psychometric properties, overall, the MOS-HIV
instrument fared better than all its counterparts. The in-
strument has minimal respondent burden and has shown
evidence of internal consistency, test-retest reliability, va-
lidity, and is responsive to changes over time. The instru-
ment has been widely used in clinical trials and has been
translated into 14 other languages, and translated forms
have been validated. CONCLUSIONS: The MOS-HIV
scale appears to be most optimal for HRQL measure-
ment in clinical trials involving HIV patients.
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OBJECTIVE: The objective of this study was to under-
stand the prescribing patterns and economic burden of
several common respiratory tract infections (RTIs) treated
in primary care. METHODS: Using eligibility and claims
data from the Lovelace Health Systems of Albuquerque,
New Mexico, we selected all outpatients treated with a
single antibiotic within 3 days of diagnosis between De-
cember 1997 and March 1999 for one of the following 4
RTIs: sinusitis, otitis media (OM), pharyngitis, and bron-
chitis. The patient’s index episode, the focus of this anal-
